NYSE$EW
Edwards Lifesciences Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported a 15 percent increase in sales, driven by growth in all product groups, despite the impact of the Delta variant.
Edwards Lifesciences reported a 15% increase in sales to $1.3 billion for the third quarter of 2021. The company's TAVR sales grew by 15%, and it made progress on five pivotal trials in TMTT. The company maintained its full-year 2021 sales guidance range and EPS guidance.
- Sales grew 15 percent to $1.3 billion; underlying sales grew 14 percent.
- TAVR sales grew 15 percent; underlying 14 percent.
- U.S. TAVR sales grew 12 percent; OUS approximately 20 percent.
- Continued progress on five pivotal trials in TMTT.
Headline financials
Revenue & EPS history
Edwards Lifesciences · Revenue · Quarterly
$1.31B
Revenue by segment
Edwards Lifesciences · $1.1B total across 3 segments · Q3 2021
- Transcatheter Aortic Valve Replacement$858M+15.2%78.2%
- Surgical Structural Heart$217M+6.7%19.8%
- Transcatheter Mitral & Tricuspid$22M+81.8%2.0%
Forward guidance
The company expects full year 2021 sales to fall within the previous guidance range of $5.2 to $5.4 billion and adjusted earnings per share guidance at the high end of $2.07 to $2.27. For the fourth quarter of 2021, the company projects sales to be between $1.30 and $1.38 billion, including TAVR between $850 and $910 million, and adjusted EPS of $0.53 to $0.59.
Tailwinds
- Full year 2021 sales guidance range unchanged
- Full year EPS guidance remains unchanged
- Company projects sales to be between $1.30 and $1.38 billion for Q4 2021
- TAVR sales for Q4 2021 projected between $850 and $910 million
- Adjusted EPS of $0.53 to $0.59 for Q4 2021
Headwinds
- Headwinds associated with the pandemic
- Some procedures were deferred in the third quarter due to the Delta variant
- TAVR sales were negatively impacted in the last two months of the third quarter due to the significant impact COVID had on hospital resources.
- Uncertainties related to the impact of the pandemic
- Potential for further deferral of procedures
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-1.3%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-1.5%
Avg return
30 days after
50%
35 / 70 earnings
Positive
+11.6%
Q1 2017
Best reaction
-31.4%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.1% | +1.9% | +7.7% | |
| Q4 2025 | +3.0% | -1.5% | +6.2% | |
| Q3 2025 | -0.8% | -0.8% | +3.8% | |
| Q2 2025 | +0.1% | +4.1% | -0.8% | |
| Q1 2025 | +6.6% | +8.3% | +6.4% | |
| Q4 2024 | +6.9% | +7.4% | -2.3% | |
| Q3 2024 | -1.7% | -1.8% | -0.2% | |
| Q2 2024 | -31.4% | -26.8% | -18.6% | |
| Q1 2024 | -2.5% | -4.4% | -0.7% | |
| Q4 2023 | +0.6% | -1.2% | +9.0% | |
| Q3 2023 | -10.9% | -11.5% | -3.7% | |
| Q2 2023 | -9.8% | -10.5% | -16.9% | |
| Q1 2023 | -1.2% | -0.3% | -6.6% | |
| Q4 2022 | +7.1% | +8.0% | +5.5% | |
| Q3 2022 | -18.3% | -16.3% | -12.0% | |
| Q2 2022 | -4.8% | -3.2% | -13.6% | |
| Q1 2022 | -8.3% | -11.7% | -17.7% | |
| Q4 2021 | -6.9% | -0.3% | +3.2% | |
| Q3 2021 | -0.4% | -1.2% | -6.4% | |
| Q2 2021 | +2.0% | +4.2% | +5.8% | |
| Q1 2021 | +7.5% | +10.0% | +4.8% | |
| Q4 2020 | -3.7% | -5.3% | -4.0% | |
| Q3 2020 | -6.0% | -7.5% | +0.1% | |
| Q2 2020 | +0.3% | -0.6% | +1.0% | |
| Q1 2020 | +3.2% | -1.6% | +1.1% | |
| Q4 2019 | -5.5% | -2.7% | -12.0% | |
| Q3 2019 | +3.0% | +6.8% | +8.4% | |
| Q2 2019 | +10.8% | +9.7% | +11.7% | |
| Q1 2019 | -0.3% | -1.2% | -4.7% | |
| Q4 2018 | -0.0% | +0.8% | +2.9% | |
| Q3 2018 | -6.0% | -6.1% | -0.7% | |
| Q2 2018 | -8.5% | -8.2% | -8.6% | |
| Q1 2018 | -5.6% | -5.8% | +0.3% | |
| Q4 2017 | +4.1% | +0.4% | +6.3% | |
| Q3 2017 | -9.4% | -10.7% | -4.6% | |
| Q2 2017 | +0.4% | -0.6% | -3.5% | |
| Q1 2017 | +11.6% | +12.0% | +16.5% | |
| Q4 2016 | -6.8% | -6.6% | -3.9% | |
| Q3 2016 | -19.5% | -17.8% | -25.8% | |
| Q2 2016 | +7.4% | +7.5% | +7.7% | |
| Q1 2016 | +0.9% | — | — | |
| Q4 2015 | +5.7% | — | — | |
| Q3 2015 | +0.7% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -1.8% | — | — | |
| Q4 2014 | +7.5% | — | — | |
| Q3 2014 | +10.9% | — | — | |
| Q2 2014 | +9.4% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | +1.0% | — | — | |
| Q3 2013 | -9.3% | — | — | |
| Q2 2013 | +2.3% | — | — | |
| Q1 2013 | -22.8% | — | — | |
| Q4 2012 | -7.1% | — | — | |
| Q3 2012 | -0.3% | — | — | |
| Q2 2012 | +4.5% | — | — | |
| Q4 2011 | -1.6% | — | — | |
| Q1 2012 | +11.6% | — | — | |
| Q3 2011 | -5.9% | — | — | |
| Q2 2011 | -3.5% | — | — | |
| Q4 2010 | +0.5% | — | — | |
| Q1 2010 | +0.5% | — | — | |
| Q1 2011 | -2.1% | — | — | |
| Q4 2008 | -1.7% | — | — | |
| Q1 2009 | -1.7% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q3 2009 | +1.3% | — | — | |
| Q2 2009 | +1.3% | — | — | |
| Q2 2010 | +1.3% | — | — | |
| Q4 2009 | +1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro